Introduction: Prostate cancer is a malignant neoplasm that exclusively affects men and is mainly found in the elderly. Despite its generally slow growth, the absence of symptoms in the early stages makes diagnosis difficult and contributes to late treatment, increasing morbidity and mortality rates. In addition, limited adherence to screening procedures, such as rectal examination and Prostate Specific Antigen (PSA) dosage, also hinders the early detection recommended for men aged 45 and over with a family history, or 50 and over for those with no family history, thus compromising the prognosis. Objectives: To analyze the incidence of prostate cancer and its screening using the PSA test in the North and Northeast regions of Brazil between 2015 and 2024. Methods: This is a cross-sectional study, collecting data from the North and Northeast between 2015 and 2024 through the Departamento de Informática do Sistema Único de Saúde (DATASUS), analyzing the outpatient production of prostate-specific antigen dosage carried out concomitantly with the incidence of prostate cancer. Results: During the analyzed time period, the Northern region had an approximate ratio of 58 PSA dosage procedures carried out for every 100 males (4,828,814 procedures for 8,251,147 individuals), a higher ratio than the Northeastern region, which had a ratio of 45 to 100 (11,777,940 tests carried out on a population of 26,310,306 men). The opposite was observed with regard to the incidence of malignant prostate neoplasia, both in absolute and relative numbers, with higher levels in the Northeast (84,695 cases, representing 0.321% of the male population) compared to the North (12,571 diagnoses, representing 0.152% of the male population). Conclusion: The analysis showed significant regional disparities regarding the performance of the featured screening test and the incidence of prostate cancer in the North and Northeast regions of Brazil between 2015 and 2024. The Northern region had a higher proportion of PSA dosages in relation to its population, which may be related to more effective screening strategies or greater adherence by the local population to preventive examinations. In contrast, the Northeast region, even with a larger population, had lower screening coverage and a higher incidence of malignant prostate neoplasms, suggesting a possible later diagnosis and consequent worsening of cases. These findings reinforce the need to intensify public policies aimed at increasing access and adherence to preventive examinations, especially in areas with lower coverage. Investments in infrastructure, professional training, educational actions and culturally appropriate awareness campaigns are essential to promote early detection, reduce mortality and ensure greater equity in cancer care between the different regions of the country.
It is with great enthusiasm that we present the Annals of the Oncology International Symposium 2025, an event that continues to solidify its significance in the oncology landscape of northern Brazil. Held in Belém, Pará, Oncology 2025 centered around the theme "The cancer control challenge: better knowing it to best facing it," dedicating itself to exploring the latest frontiers in cancer treatment and prevention.
This year, the symposium provided a deep dive into the essential role of knowledge in the fight against cancer, presenting new perspectives and scientific advancements across various areas of oncology. Renowned global experts gathered to share their most recent research and innovative approaches, offering participants a comprehensive view of the challenges faced by healthcare professionals and patients worldwide.
Presentations and discussions during the event focused on critical topics such as the use of new technologies, advancements in personalized therapies, and more effective prevention strategies. Additionally, particular attention was given to the unique challenges faced by the Amazon region, with efforts aimed at developing region-specific solutions to meet local needs.
Beyond being a high-caliber academic event, Oncology 2025 stood out as a moment for integration and professional networking, with the warm hospitality of the city of Belém offering participants a unique experience. This event became a platform for exchanging ideas, where science, culture, and humanity came together in pursuit of a common goal: to improve cancer control both in Brazil and globally.
This collection of abstracts and articles presented during the event reflects the ongoing dedication to research and the development of innovative solutions, highlighting the importance of collaboration and shared knowledge in the fight against cancer.
General Submission Guidelines:
The presenting author, who does not have to be the first author, must be registered for Oncology 2025.
Each abstract may have up to 10 authors, including the main author and co-authors.
Only original, unpublished work will be accepted.
Submissions must be related to oncology. However, project descriptions, work proposals, experience reports, and literature reviews will not be considered.
Clinical case reports are allowed, provided the abstract addresses scientific questions, details clinical observations, and includes primary scientific data.
The abstract must be written in English, but presentations may be given in Portuguese.
Abstracts must be between 300 and 500 words.
Comissão Organizadora
Comissão Científica
See Annals of Oncology 2023 at:
https://www.even3.com.br/anais/oncology-2023-international-symposium/
Complete tool for submission, evaluation and publication of proceedings for scientific events.
